Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-APOC3
Arrowhead Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ARO-APOC3 for the treatment of familial chylomicronemia…
Read More...
Read More...
